On June 21, Gelunhui | innocare (688428.SH) rose more than 5%, with a reported price of 7.77 yuan, with a current trading volume of 68 million yuan, which is the same as the total trading volume of yesterday. The total market value is 13.7 billion yuan. In terms of news, the company announced that the National Medical Products Administration (NMPA) has accepted the biologics license application (BLA) for the listing of CD19 monoclonal antibody Tafasitamab in combination with lenalidomide for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in adults who are not suitable for autologous stem cell transplantation. It has been included in priority review. DLBCL is the most common type of non-Hodgkin's lymphoma (NHL), accounting for 31% to 34% of NHL cases worldwide. In China, DLBCL accounts for 45.8% of all NHL cases.
A股异动丨诺诚健华涨超5% 创新药生物制品许可获受理
A-shares change｜Innocare's stock rises more than 5%, innovative drugs and biological products licenses have been accepted for review.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.